Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children’s Oncology Group

[1]  Michael W. Bishop,et al.  The Cumulative Burden of Surviving Childhood Cancer: An Initial Report from the St. Jude Lifetime Cohort Study , 2017, The Lancet.

[2]  S. Lipshultz,et al.  Chemotherapy-induced cardiotoxicity in children , 2017, Expert opinion on drug metabolism & toxicology.

[3]  M. Hauptmann,et al.  Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Lipshultz,et al.  Prevention of cardiotoxicity among survivors of childhood cancer , 2017, British journal of clinical pharmacology.

[5]  H. Youn,et al.  Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab , 2017, Journal of breast cancer.

[6]  W. Leisenring,et al.  Effect of Dexrazoxane on Heart Function Among Long-Term Survivors of Childhood Leukemia and Lymphoma: A Report from the Children's Oncology Group (COG) , 2016 .

[7]  S. Lipshultz,et al.  Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  D. Neuberg,et al.  Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin‐treated childhood acute lymphoblastic leukemia survivors , 2016, Cancer.

[9]  S. Lipshultz,et al.  Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group , 2016, Pediatric blood & cancer.

[10]  W. Leisenring,et al.  Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Seif,et al.  Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients , 2015, Pediatric blood & cancer.

[12]  S. Lipshultz,et al.  A review of the preclinical development of dexrazoxane , 2014 .

[13]  S. Sallan,et al.  Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer: An update of the evidence , 2014 .

[14]  A. Seif,et al.  Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: Analysis of a national cohort of patients in the pediatric health information systems database , 2013, Pediatric blood & cancer.

[15]  S. Lipshultz,et al.  Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  L. Moja,et al.  Trastuzumab containing regimens for early breast cancer. , 2012, The Cochrane database of systematic reviews.

[17]  S. Lipsitz,et al.  Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. Neuberg,et al.  The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. , 2011, European journal of cancer.

[19]  G. Mancia,et al.  Low anthracyclines doses‐induced cardiotoxicity in acute lymphoblastic leukemia long‐term female survivors , 2010, Pediatric blood & cancer.

[20]  S. Colan,et al.  Serial measurements of serum NT-proBNP as markers of left ventricular systolic function and remodeling in children with heart failure. , 2010, American heart journal.

[21]  S. Lipsitz,et al.  Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. , 2010, The Lancet. Oncology.

[22]  S. Lipshultz,et al.  Cardiotoxicity after childhood cancer: beginning with the end in mind. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Fiuza.  Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer , 2009, Advances in therapy.

[24]  G. Armstrong,et al.  Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Neuberg,et al.  Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  L. Constine,et al.  Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  S. Lipsitz,et al.  Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  P. Hildebrandt,et al.  N-Terminal Pro-Brain Natriuretic Peptide, C-Reactive Protein, and Urinary Albumin Levels as Predictors of Mortality and Cardiovascular Events in Older Adults , 2005 .

[29]  E. Kleinerman,et al.  Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  L. Køber,et al.  N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. , 2005, The New England journal of medicine.

[31]  S. Lipsitz,et al.  The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. , 2004, The New England journal of medicine.

[32]  G. Martinelli,et al.  Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy , 2004, Circulation.

[33]  S. Colan,et al.  Cardiovascular trials in long-term survivors of childhood cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  D. Keefe,et al.  Trastuzumab‐associated cardiotoxicity , 2002, Cancer.

[35]  C. Hudis,et al.  Cardiac dysfunction in the trastuzumab clinical trials experience. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  W. Winkelmann,et al.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  S. Lipsitz,et al.  Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. , 1997, Circulation.

[38]  V. Dilsizian,et al.  Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  E J Orav,et al.  Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. , 1995, The New England journal of medicine.

[40]  S. Colan,et al.  Developmental modulation of myocardial mechanics: age- and growth-related alterations in afterload and contractility. , 1992, Journal of the American College of Cardiology.

[41]  R. Simon,et al.  Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. , 1991, Journal of the National Cancer Institute.

[42]  S. Colan,et al.  Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. , 1991, The New England journal of medicine.

[43]  T. Alonzo,et al.  Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children's Oncology Group. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  J. Stockman.  Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort , 2011 .

[45]  W. Frishman.  N-Terminal Pro-B-Type Natriuretic Peptide and Longterm Mortality in Stable Coronary Heart Disease , 2006 .

[46]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[47]  M. Bates,et al.  A pharmacoeconomic evaluation of the use of dexrazoxane in preventing anthracycline-induced cardiotoxicity in patients with stage IIIB or IV metastatic breast cancer. , 1997, Clinical therapeutics.

[48]  J. Silber,et al.  Increased risk of cardiac dysfunction after anthracyclines in girls. , 1993, Medical and pediatric oncology.

[49]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .